期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

ER、PR、C-erbB-2和Ki-67在乳腺癌新辅助化疗前后中的表达及意义 被引量：3

Expression and significance of ER,PR,C-erbB-2 and Ki-67 before and after neo-adjuvant chemotherapy in breast cancer
下载PDF
导出
摘要 目的探讨新辅助化疗(NAC)对乳腺癌组织中雌激素受体(estrogen receptor,ER)、孕激素受体(progesterone receptor,PR)C-erbB-2和Ki-67表达及意义。方法采用免疫组化S-P法检测化疗前后56例乳腺癌组织中ER、PR、C-erbB-2和Ki-67的表达。结果新辅助化疗前后ER、PR和C-erbB-2的表达无明显变化(P>0.05)。新辅助化疗前后Ki-67的表达差异有统计学意义(P<0.05)。结论新辅助化疗能显著降低Ki-67的表达,对ER、PR和C-erbB-2的表达状态无明显影响。新辅助化疗后检测可为后续治疗和判断预后提供指导。 Objective To study the expression and significance of ER,PR, C-erbB-2 and Ki-67 before and after neo-adjuvant chemotherapy in patients with breast cancer. Methods The immunohistochemical staining method was used to examine the expression of ER, PR, C-erbB-2 and Ki-67. Results The expression of ER,PR and C-erbB-2 had no significant difference after neo-adjuvant chemotherapy as compared with before neo-adjuvant chemotherapy （ P 〉 0. 05 ）. The expression of Ki-67 significantly difference after neo-adjuvant chemotherapy as compared with before neo-adjuvant chemotherapy（ P 〈 0. 05 ）. Conclusion The expression of Ki-67 is decreased after neo-adjuvant chemotherapy. Neo-adjuvant chemotherapy has no significant influence on the expression of ER,PR and C-erbB-2.
作者 姚永强 曹铭谦 张殿龙 方红 解继平
机构地区 大连大学附属中山医院普外三科
出处 《中国现代药物应用》 2009年第23期9-11,共3页 Chinese Journal of Modern Drug Application
关键词 乳腺肿瘤 新辅助化疗 ER PR C-ERBB-2 KI-67 Breast cancer Neoadjuvant chemotherapy ER PR C-erbB-2 Ki-67
分类号 R737.9 [医药卫生—肿瘤] R984 [医药卫生—药品]
  • 相关文献

参考文献9

  • 1Bonadonna G, Valagussa P, Brambilla C, et al. Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol, 1998,16:93-100.
  • 2Bottini A, Berruti A, Bersiga A, et al. Effect of neoadjuvant chemotherapy on Ki-67 labelling index, c-erbB-2 expression and steroid hormone receptor status in human breast tumours. Anticancer Research, 1996,16(5B) :3105-3110.
  • 3Lee SH, Chung MA, Quddus MR, et al. The effect of neoadjuvant chemotherapy on estrogen and progesterone receptor expression and hormone receptor status in breast cancer. Am J Surg, 2003,186: 348-350.
  • 4王殊,张嘉庆,乔新民,杨德启,佟富中,刘宏军.新辅助化疗对乳腺癌雌孕激素受体表达的影响[J].中华外科杂志,2005,43(15):1011-1013. 被引量：9
  • 5Tsutsui S, Ohno S, Murakami S, et al. Prognostic value of C-erbB-2 expression in breast cancer. J Surg Oncol,2002,79(4) :216.
  • 6Bems EM, Foekens JA,Van Stavern IL, et al. Oncogene amplification and progness in breast cancer:relationship with systemictreatment. Gene, 1995,159 ( 1 ) : 11-18.
  • 7Dagrda GP, Mezzlani A, Alasio L, et al. Her-2/neu assessment in primary chemotherapy treated breast carcinoma: no evidence of gene profile changing. Breast Cancer Research and Treatment, 2003,80:207-214.
  • 8Petit T, Burel C, Ghnassia JP, et al. Chemotherapy response of breast cancer depends on C-erbB-2 status and anthreacycline dose intensity in the neoadjuvana setting. Clinical Cancer Research, 2001,7:1577-1581.
  • 9Faneyte IF, Schrama JG, Peterse JL, et al. Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. British journal of Cancer,2003,88:406-412.

二级参考文献13

  • 1Harvey JM, Clark GM, Osborne CK, et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol, 1999, 17 : 1474-1481.
  • 2Goldhirsch A, Glick JH, Gelber RD, et al. Meeting highlights:International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol, 2001, 19:3817-3827.
  • 3Mamounas EP, Fisher B. Preoperative (neoadjuvant) chemotherapy in patients with breast cancer. Semin Oncol, 2001, 28:389-399.
  • 4van der Hage JA, van de Velde C J, Julien JP, et al. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol, 2001,19:4224-4237.
  • 5Bonadonna G, Valagussa P, Brambilla C, et al. Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol, 1998 , 16:93-100.
  • 6Bottini A, Berruti A, Bersiga A, et al. Effect of neoadjuvant chemotherapy on Ki67 labelling index, c-erbB-2 expression and steroid hormone receptor status in human breast turnouts. Anticancer Res, 1996,16:3105-3110.
  • 7Schneider J, Lucas R, Sanchez J, et al. Modulation of molecular marker expression by induction chemotherapy in locally advanced breast cancer: correlation with the response to therapy and the expression of MDR1 and LRP. Anticancer Res, 2000 , 20 : 4373-4377.
  • 8Jain V, Landry M, Levine EA. The stability of estrogen and progesterone receptors in patients receiving preoperative chemotherapy for locally advanced breast carcinoma. Am Surg,1996, 62 : 162-165.
  • 9Lee SH, Chung MA, Quddus MR, et al. The effect of neoadjuvant chemotherapy on estrogen and progesterone receptor expression and hormone receptor status in breast cancer. Am J Surg, 2003, 186:348-350.
  • 10Eifel P, Axelson JA, Costa J, et al. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer lnst, 2001,93 :979-989.

共引文献8

同被引文献27

  • 1尹子毅,刘晖,李洪利,王丕琳,张铁,宋茂民.乳腺癌组织p53和Ki-67表达及其与新辅助化疗关系的研究[J].中华肿瘤防治杂志,2008,15(9):676-678. 被引量：10
  • 2沈镇宙,柳光宇,苏逢锡,何萍青,杨名添,施俊义,盛援,邹强,李亚芬.多西紫杉醇加表柔比星治疗局部晚期乳腺癌的多中心Ⅱ期临床研究[J].中华肿瘤杂志,2005,27(2):126-128. 被引量：56
  • 3王殊,张嘉庆,乔新民,杨德启,佟富中,刘宏军.新辅助化疗对乳腺癌雌孕激素受体表达的影响[J].中华外科杂志,2005,43(15):1011-1013. 被引量：9
  • 4Markhoul I,Kiwan E. Neoadiuvant systemic treatment of breast cancer[J]. J Surg Oncol, 2011,103 (4): 348-357.
  • 5魏少琳.三阴性乳腺癌的新辅助化疗的疗效及预后对比分析[J].中国煤炭医学杂志,2010,13(11):1621-1622.
  • 6Nishimura R,Osako T,Okumura Y, et al. Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis[J]. Breast Cancer,2010,17(4) :269-275.
  • 7Gralow JR,Burstein HJ,Wood W, et al. Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease[J]. J Clin Oncol, 2008,26(5) : 814-819.
  • 8Fisher B,Bryant J,Wolmark N,et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer[J]. J Clin Oncol, 1998,16(8) :2672-2685.
  • 9Bear HD,Anderson S, Brown A,et al. The effect on tumor response of adding sequential preoperative docetaxel to preoprative doxorubicin and cyclophosphamide; preliminary results from national surgical adjuvant breast and bowel project protocol B-27 [J]. J Clin Oncol,2003,21(22) ,4165-4174.
  • 10Taucher S, Rudas M, Gnant M, et al. Sequential steroid hormone receptor measurements in primary breast cancer with and without intervening primary chemotherapy[J]. Endocr Relat Cancer, 2003,10(1) : 91-98.

引证文献3

二级引证文献18

中国现代药物应用
2009年 第23期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部